Dr. Joshua Smith is a research scientist and team lead for IBM’s Nanobiotechnology Program.
Around forty percent of the population will receive a cancer diagnosis within their lifetime. Accurate early diagnosis drastically increases the survival rate of most cancers. Current methods for diagnosis are invasive, costly, and not reliably accurate.
Dr. Joshua Smith and his team aim to create a non invasive cancer diagnostic tool that can be implemented into regular screenings.
They created nano technology capable of sorting and isolating exosome genetic material to expedite cancer diagnostics. Their approach is called deterministic lateral displacement; it is a chip based, continuous flow separation that allows for the isolation of bio markers on the surface of the exosomes.